Compared with oral administration, continuous subcutaneous infusion of carbidopa/levodopa was linked to nearly 2 more hours of “on” time without dyskinesia in adults with Parkinson’s disease ...

Of 270 screened participants, 141 were randomly assigned to receive continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo capsules (n = 74) or oral encapsulated immediate ...

Researchers sought to determine whether adding subcutaneous rituximab to CHOP would improve outcomes for patients with DLBCL in low-resource settings.

Ocrevus subcutaneous injection was non-inferior to Ocrevus IV infusion as measured by Ocrevus levels in the blood of patients (area under the serum concentration time curve) from day 1 to 12 weeks ...

In this single arm, open-label study, they received subcutaneous infusions of personalized therapeutic doses of fosL/fosC 24 hours/day for 28 days after a 10- to 30-day screening period during ...

Meeting Coverage > ECTRIMS Subcutaneous Ocrelizumab Not Inferior to IV Infusion — Both provided rapid B-cell depletion by Judy George, Deputy Managing Editor, MedPage Today October 14, 2023 ...

Surf Bio, a biopharmaceutical company transforming the delivery of antibodies and biologics, announced today that a peer-reviewed study conducted by researchers at Stanford University and published in ...

KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world.

Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 ...

These results, with the KORU Freedom Infusion System, also demonstrate the company’s potential to support a broader range of developmental subcutaneous drug therapies.” About KORU Medical Systems ...

Written by Zacks Equity Research for Zacks -> KORU Medical Systems, Inc. KRMD has made a strategic move in its pursuit of expanding its footprint in the realm of large-volume subcutaneous infusion.

Ocrevus subcutaneous injection was non-inferior to Ocrevus IV infusion as measured by Ocrevus levels in the blood of patients (area under the serum concentration time curve) from day 1 to 12 weeks ...